College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Republic of Korea.
Department of Family Medicine, CHA Bundang Medical Center, CHA University, Republic of Korea.
Arch Gerontol Geriatr. 2018 Jan;74:1-8. doi: 10.1016/j.archger.2017.08.013. Epub 2017 Sep 6.
To investigate the prevalence of potentially inappropriate prescribing (PIP) of central nervous system and psychotropic (CNS-PS) drugs to the Korean elderly population, and to identify PIP-associated factors.
Ambulatory care visits were identified from the 2013 National Aged Patient Sample (HIRA-APS-2013) data, composed of 20% random samples of all enrollees in the universal health security program aged ≥65 years. The CNS-PS section of Screening Tool of Older Person's potentially inappropriate Prescriptions (STOPP) criteria version 2 was used to identify PIP at these visits.
A total of 24,427,069 prescription claims records and 1,122,080 patients were included in the study; 10.73% of the claims and 53.64% of the patients satisfied at least one STOPP criterion in the prescription of CNS-PS drugs. The highest prevalence of PIP was observed for the criteria of "first-generation antihistamines" (FGAH), followed by tricyclic antidepressants (TCA) in patients with prostatism and TCA in patients with dementia. The generalized estimating equation logistic regression analysis showed that the PIP of FGAH was significantly associated with polypharmacy (5-9 drugs: odds ratio (OR) 4.965, 95% confidence interval (CI) 4.936-4.994; ≥10 drugs: OR 5.704, 95% CI 5.604-5.807), less severe health conditions (Charlson Comorbidity Index (CCI)=2: OR 0.852, 95% CI 0.842-0.862; CCI=1: OR 0.975, 95% CI 0.964-0.986), prescriptions from clinics (OR>1.0), and outpatient care by general practitioners (OR>1.0).
Appropriate interventions to reduce PIP should be made, especially for the criteria that indicate a high PIP prevalence. Targeted strategies are necessary to modify the risk factors of PIP identified from this study.
调查韩国老年人群中中枢神经系统和精神药物(CNS-PS)潜在不适当处方(PIP)的流行情况,并确定与 PIP 相关的因素。
从 2013 年国家老年患者抽样调查(HIRA-APS-2013)数据中确定门诊就诊,该数据由参加全民健康保障计划的所有 65 岁以上老年人的 20%随机样本组成。使用老年人潜在不适当处方筛选工具(STOPP)第 2 版的 CNS-PS 部分来识别这些就诊时的 PIP。
共纳入 24427069 份处方和 1122080 名患者;在 CNS-PS 药物处方中,10.73%的处方和 53.64%的患者至少符合一个 STOPP 标准。PIP 发生率最高的标准是“第一代抗组胺药”(FGAH),其次是前列腺增生患者的三环类抗抑郁药(TCA)和痴呆患者的 TCA。广义估计方程逻辑回归分析显示,FGAH 的 PIP 与多药治疗(5-9 种药物:比值比(OR)4.965,95%置信区间(CI)4.936-4.994;≥10 种药物:OR 5.704,95%CI 5.604-5.807)、健康状况较轻(Charlson 合并症指数(CCI)=2:OR 0.852,95%CI 0.842-0.862;CCI=1:OR 0.975,95%CI 0.964-0.986)、诊所处方(OR>1.0)和全科医生门诊治疗(OR>1.0)显著相关。
应采取适当措施减少 PIP,特别是针对表明 PIP 发生率较高的标准。需要有针对性的策略来修改从本研究中确定的 PIP 危险因素。